bluebird bio Inc. | Balance Sheet

Fiscal year is January-December. All values USD Millions.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
206
474
518
704
1,290
1,386
Total Accounts Receivable
-
-
-
-
8
-
Other Current Assets
6
6
6
20
25
33
Total Current Assets
212
480
524
724
1,323
1,419
Net Property, Plant & Equipment
11
16
83
157
200
247
Total Investments and Advances
1
18
348
180
324
520
Long-Term Note Receivable
-
-
-
-
14
-
Intangible Assets
-
41
38
34
30
26
Other Assets
-
1
10
23
10
31
Total Assets
224
557
1,002
1,118
1,901
2,243
ST Debt & Current Portion LT Debt
-
-
-
-
1
Accounts Payable
4
3
6
14
13
Other Current Liabilities
31
40
34
61
82
Total Current Liabilities
35
43
40
75
96
Long-Term Debt
-
-
62
120
155
Provision for Risks & Charges
-
6
5
3
-
Deferred Taxes
-
2
-
-
-
Other Liabilities
38
14
44
51
27
Total Liabilities
73
65
152
249
277
Common Equity (Total)
152
491
850
869
1,623
Total Shareholders' Equity
152
491
850
869
1,623
Total Equity
152
491
850
869
1,623
Liabilities & Shareholders' Equity
224
557
1,002
1,118
1,901

About bluebird bio

View Profile
Address
60 Binney Street
Cambridge Massachusetts 02142
United States
Employees -
Website http://www.bluebirdbio.com
Updated 07/08/2019
bluebird bio, Inc. is a clinical-stage biotechnology company. Its integrated product platform includes gene therapy, cancer immunotherapy, and gene editing. It offers the LentiGlobin which is a treatment for transfusion-dependent ß-thalassemia; and Lenti-D as a treatment for cerebral adrenoleukodystrophy.